Burning Rock Biotech (FRA:6BU0) Moat Score: 3/10 (As of Jul. 12, 2026)


FRA:6BU0 Burning Rock Biotech Ltd FRA:6BU0
66 GF Score
Price €9.10
GF Value €8.99
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Moat Score?

Burning Rock Biotech FRA:6BU0 -9.00% 66 Moat Score is 3 as of Jul. 12, 2026. GuruFocus rates FRA:6BU0 with a GF Score™ of 66/100 and a GF Value™ of €8.99 (Fairly Valued). The stock has 2 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 76.74% on this metric.

Burning Rock Biotech has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Burning Rock Biotech has No Moat: Burning Rock Biotech operates in a highly competitive biotech industry with limited market leadership and lacks significant customer switching costs or brand strength. It does not have durable cost advantages or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Burning Rock Biotech might have No Moat - Very weak/transient advantages.

Burning Rock Biotech  (FRA:6BU0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Burning Rock Biotech Moat Score Related Terms

FRA:6BU0 vs XGN, IDXG, PRPO: Moat Score Comparison

For the Diagnostics & Research subindustry, Burning Rock Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Moat Score falls into.


FRA:6BU0
66GF Score
Burning Rock Biotech Ltd FRA:6BU0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Burning Rock Biotech (FRA:6BU0) has a Moat Score of 3 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Burning Rock Biotech ranks #50 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 23.3%.
Is Burning Rock Biotech's Moat Score too high?
Burning Rock Biotech's current Moat Score is 3. Based on the distribution chart, Burning Rock Biotech ranks #50 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Moat Score compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #50 out of 215 companies for Moat Score. This places Burning Rock Biotech in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Burning Rock Biotech's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Fairly Valued. The stock's GF Value™ is €8.99, compared to a current price of €9.10 — trading 1.2% above its estimated fair value. The current Moat Score is 3. Burning Rock Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Moat Score is 3 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of €9.10 is trading 1.2% above its estimated GF Value™ of €8.99. GuruFocus considers Burning Rock Biotech to be Fairly Valued.

Key valuation signals for FRA:6BU0:

  • Moat Score: 3
  • GF Value™: €8.99 vs. price of €9.10 (1.2% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges BNR:USA
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
66GF Score

Get the complete analysis for FRA:6BU0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.10
Price
€8.99
GF Value